Fig. 1From: Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature reviewSummary of the treatment received by the patient, including the best objective response (OR) and progression-free survival (PFS) in each line of treatment. Abdominal computed tomography (CT) scans are also provided. Red arrows indicate the primary lesionsBack to article page